Literature DB >> 26375389

Metastatic Cutaneous Apocrine Adenocarcinoma Treated With a Combination of Pertuzumab-Based Targeted Therapy and Taxane Chemotherapy: A Case Report.

Masaki Otsuka1, Osamu Yamasaki2, Tatsuya Kaji2, Tadahiko Shien3, Keiji Iwatsuki2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26375389     DOI: 10.1001/jamadermatol.2015.2507

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

1.  Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

Authors:  Rami Mäkelä; Ville Härmä; Nibal Badra Fajardo; Greg Wells; Zoi Lygerou; Olle Sangfelt; Juha Kononen; Juha K Rantala
Journal:  Oncotarget       Date:  2021-05-25

2.  Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation.

Authors:  Brian P Hibler; Christopher A Barker; Travis J Hollmann; Anthony M Rossi
Journal:  JAAD Case Rep       Date:  2017-05-27

3.  Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab.

Authors:  Sadanori Furudate; Taku Fujimura; Akira Tsukada; Yota Sato; Takanori Hidaka; Kayo Tanita; Yumi Kambayashi; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2017-01-16

Review 4.  A case of eccrine porocarcinoma characterized by a progressive increase in the level of Ki-67 index: case report and review of literature.

Authors:  Jie Shen; Xinfa Pan; Yongfu Lu; Desheng Pan; Yuehui Ma; Renya Zhan
Journal:  BMC Surg       Date:  2019-10-10       Impact factor: 2.102

Review 5.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.